A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PRX002 Administered By Intravenous Infusion in Patients With Parkinson's Disease
Latest Information Update: 22 Jun 2018
Price :
$35 *
At a glance
- Drugs Prasinezumab (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Prothena
- 19 Jun 2018 Results presented in a Prothena Corporation media release.
- 19 Jun 2018 Results from this trial published in JAMA Neurology media release, according to a Prothena Corporation media release.
- 18 Jun 2018 Results published in the JAMA Neurology